Lonza
Lonza is a Swiss chemicals contract development and manufacturing company (CDMO) operating across small molecules, biologicals, cell and gene, capsules, and health ingredients. CDMOs enable the use of state-of-the-art technology and equipment, bring scale, expertise and excellence to pharmaceutical manufacturing. CDMOs enable customers to deliver new, innovative medicines that help treat a wide range of diseases and accelerate the process to achieve commercial scale production. This results in lower cost and more effective medicines.
Visit their site- Enterprise value
- US$42.8 bn
- Region
- Switzerland
- Theme
- Health
- Sub-theme
- Pharmaceutical therapies
Impact Score
Over half of drug development is now aided by CDMOs, meaning a wide applicability across the pharmaceutical industry and within healthcare, and Lonza is the largest CDMO in the market. The company is purely focused on the manufacturing part of the value-chain with the key drug development steps taking place elsewhere. Drugs account for a relatively small proportion (10-20%) of total healthcare spending.
Fundamental Quality
Lonza is a very high-quality company that is set to benefit from a growing trend towards outsourcing manufacturing. Its competitive position is also protected by the increasing complexity of biologics which increase the barriers to entry.
UN SDGs
Lonza’s services support SDG 3 by enabling the production of lower cost, more effective medicines.
Find out moreRisk of negative impacts
- Animal testing of pharmaceuticals (not done by Lonza)
- Manufacturing produces medical waste including plastics and toxic chemicals
- Manufacturing requires a substantial amount of water
Related insights Related
Sustainable
The next constraint on AI is not just energy, it's also water
By Ty Lee
10 Mar 2026 | 3 min read
Sustainable
From villain to saviour – renewable energy is coming to the rescue
By WHEB Investment Team
17 Feb 2026 | 6 min read
Sustainable
Are EVs really rolling backwards?
By WHEB Investment Team
19 Jan 2026 | 5 min read
Sustainable
Sustainable investment trends for 2026
By Seb Beloe
19 Jan 2026 | 5 min read